SOT Therapy for Lyme and Other Infections

Supportive Oligonucleotide Therapy (SOT) is a process that enables the lab to find the specific gene sequences of different targets such as cancer, Lyme, and various viruses and design a specific oligonucleotide therapy. The SOT is uniquely tailored to each patient’s needs. It is a small oligonucleotide which is complementary to a specific sequence of individual genes which are related to anti-apoptotic signals inside cancer cells, or genes essential for microorganisms and viruses’ survival or metabolism.

Apoptosis is another word for programmed cell death. In other words, the SOT molecule has a potent ability to block specific mRNA with an extremely high rate of specificity, therefore expression of desired gene is inhibited.

A patient’s blood is sent to the lab where the scientists find the appropriate gene that needs to be silenced. Once they detect the potential genes for targeting, they confirm these targets both in silico and in vitro. The validation of target ensures the highest specificity and does not interfere with any other targets. Once the different target genes have been confirmed, then the most appropriate gene is selected and the laboratory creates an oligonucleotide, complementary to the mRNA for a specific region of this gene. This in turn creates an anti-sense therapy.

These molecules are delivered to the clinic where the patient receive the one dose IV treatment. Once the patient receives the SOT molecules, they are at work 24 hours a day, seven days a week for up to six months, inhibiting the appropriate gene.

Apoptosis is another word for programmed cell death. In other words, the SOT molecule has a potent ability to block specific mRNA with an extremely high rate of specificity, therefore expression of desired gene is inhibited.

To inhibit the expression of proteins which are essential for cell metabolism and/or survival.

• Herpes simplex virus 1 Herpes simplex virus 2
• Human herpesvirus 6
• Cytomegalovirus
• Coxsackie Type A, B
• Varicella zoster virus
• Epstein–Barr virus
• Human papillomavirus 6, 11, 16, 18
• Hepatitis B
• Hepatitis C
• human immunodeficiency virus
• Human T-lymphotropic virus 1

• Borrelia burgdorferi and 18 other subspecies
• Bartonella henselae and 5 other subspecies
• Babesia duncani and 5 other subspecies
• Anaplasma
• Rickettsia
• Ehrlichia

The SOT THERAPY only

Yes, they have been assessed in thousands of studies for their safety.

• Pregnancy or breast feeding
• Recent blood transfusion
• Recent cytotoxic chemotherapy and/or radiotherapy
• Radioactive Seed Therapy
• Delta Cell Therapy (GDTC)
• Children under the age of 5

Note: See full list of substances/therapies/treatments and associated timelines below under “What Needs to be Avoided for SOT Therapy.”

SOT for Lyme for children over the age of 5 (Reason: the sequence of interest has no overlapping parts with human genome)

While SOT is well tolerated, when dealing with living pathogens in a human body there are potential side effects even with a gene silencing therapy like SOT. Some of the common side effects we’ve seen have been:

• • Headaches
  • Increased fatigue
  • Flu like symptoms
  • Herxheimer reactions can occur
  • Co-infections can flare

• Positive test result confirming presence of the targeted pathogen.
• Test result can be PCR or antibody result.
• Test result must be serum-based results (urine will be accepted)
• Test result must be within six (6) months (date of reporting)
• Tests must be from a reputable lab.

• Mandatory: 4 mg dexamethasone I.V. in a 20-50 ml rapid drip saline solution or slow bolus push in order to counteract the possibility of extravasation of the IV application by stabilizing the veins lumen and allowing more normal distribution of the therapy.
• Optional: Famotidine and Acetaminophen are optional but routinely administered as an extra caution at the healthcare providers discretion.

The patient must be off all therapies for 14 days prior to the blood draw for the SOT. This includes:

• • • Antibiotics (oral or IV)
    • Antiviral medications (oral or IV)
    • Anti-parasitic medications (oral or IV)
    • Vitamin C (IV)
    • Colloidal Silver (oral or IV)
    • H2O2 IV
    • Ozone (IV)
    • Natural Substances (ALL oral supplements that are trying to kill or suppress the same target as the SOT)

• It is recommended to administer the SOT at full dose, however when thought necessary by the healthcare provider, it can be split into half doses.
• The second half must be stored -17 to -23 degrees and given in 21 – 30 days.
• If the second half needs to be given over 30 days, it must be stored at -80 degrees.

15-25ml whole blood in RGCC vials (1 glass vial)

NOTE: If ordering one to three SOTs, can send in one full vial of 30ml)

• Each SOT has a life span of six (6) months.
• SOT in the dried form can be stored for up to six months if kept at room temperature and protected from light.
• SOT after reconstitution can be stored in -17 to -23 degrees for up to 21 days.
• Longer than 21 days it needs to be stored at -80 degrees.

• Maximum of nine (9) total in a 12-month period (must be spaced at least seven (7) days apart)
• Maximum of four (4) total for the same target in a 12-month period (must be spaced at a minimum of (3) three months apart and must supply updated test result that shows the pathogen is still present before a repeat for the same pathogen will be allowed)

NOTE: SOTs work for a long time and can accumulate in the body and build up

There is a minimum of seven (7) days between two different SOTs. It is never recommended to give more than one SOT on the same day.

• No other therapies are allowed on the same day as SOT administration.

All therapies may be resumed (as outlined above) 7 days after administration.

Note: Biofilm busters are recommended after SOT infusion to expose added targets for the SOT.

Note: Detox supplements such as binders, glutathione, cytokine reducers, etc. will not interfere with the action of the SOT and can be used both pre and post SOT administration. Oral supplements like multi-vitamins, vitamin D, probiotics, etc. also do not need to stop pre or post SOT administration.

The same lab that was used to order the SOT should be used to evaluate the status of the pathogen 3-4 months after the SOT administration.

No, the SOT targets only a specific region of a gene. If a patient has multiple active infections, then multiple SOT treatments will be needed. One for each infection since each target has its own unique DNA sequence.

• Virus Infected Patients: The positive clinical outcome reached 91%
• Lyme Disease: Approximately 95% of cases had a positive clinical outcome.